Francesca Palandri: Prioritizing Anemia Matters in Myelofibrosis
Francesca Palandri, Hematologist at Sant’Orsola-Malpighi Polyclinic – Bologna University Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Clinical Lymphoma, Myeloma and Leukemia, adding:
“Prioritizing anemia matters in myelofibrosis.
Happy to share our latest subgroup analysis from the phase III SIMPLIFY-1 trial, now published in Clinical Lymphoma, Myeloma Leukemia.
We examined momelotinib vs. ruxolitinib in JAK inhibitor–naive myelofibrosis patients with anemia (Hb 10 g/dL).
Key Findings:
- Momelotinib achieved higher dual response rates (spleen reduction and transfusion independence) vs. ruxolitinib: 27% vs. 7%
- In patients with platelets 200 × 10⁹/L, momelotinib showed superior spleen response: 39% vs. 17%
- Transfusion independence correlated with significantly improved overall survival (HR 0.25–0.40)
Prioritizing transfusion independence in anemic MF patients and suggest momelotinib may be preferred in those with lower platelet counts.
Honored to serve as first author of this collaborative work together with an outstanding group of colleagues.
A big thank-you to all my colleagues at IRCCS Policlinico di Sant’Orsola – Azienda Ospedaliero Universitaria di Bologna.”
Title: Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1
Authors: Francesca Palandri, Nicolaas P M Schaap, Jerome Rey, Nikolas von Bubnoff, Andreas Reiter, Juan Carlos Hernandez-Boluda, Timothy Devos, Lars Nilsson, Bethan Psaila, Donal P McLornan, Bryan Strouse, Shiyuan Zhang, Bharat Patel, Jessica Lim, Dwaipayan Patnaik, Stephen T Oh
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering